Heart Failure with Reduced Ejection Fraction (HFrEF) — Diagnosis and Management
Diagnose HFrEF with transthoracic echocardiography demonstrating LVEF ≤40% in a patient with signs and symptoms of heart failure, supported by elevated NT-proBNP ≥300 pg/mL. Initiate all four pillars of guideline-directed medical therapy simultaneously: sacubitril-valsartan 24/26 mg BID, carvedilol 3.125 mg BID, spironolactone 25 mg daily, and dapagliflozin 10 mg daily. Classify functional limitation using the NYHA classification (I–IV) and stage disease severity with the ACC/AHA staging system (A–D). Refer for ICD if LVEF remains ≤35% after 3 months of optimized GDMT, and evaluate for advanced therapies (LVAD, transplant) in Stage D refractory disease.
Pathophysiology
Heart failure with reduced ejection fraction results from impaired myocardial contractility that reduces the left ventricle’s ability to eject blood into the systemic circulation, triggering a cascade of maladaptive neurohormonal responses. The initial insult—whether ischemic injury, chronic volume overload, or direct myocardial toxicity—leads to cardiomyocyte loss and ventricular remodeling, characterized by progressive chamber dilation, wall thinning, and transition from an elliptical to a spherical geometry. This geometric distortion increases wall stress as described by the Laplace relationship, further impairing systolic function and creating a self-perpetuating cycle of deterioration.
- Core Mechanism
- Reduced myocardial contractility with LVEF ≤40%, triggering compensatory neurohormonal activation (RAAS, sympathetic nervous system) that initially maintains cardiac output but ultimately accelerates ventricular remodeling and disease progression
- Key Pathway
- Decreased cardiac output → baroreceptor unloading → sympathetic activation + RAAS activation → norepinephrine/angiotensin II/aldosterone release → vasoconstriction + sodium/water retention + myocardial fibrosis → increased preload/afterload → progressive LV dilation
- Genetic Factors
- TTN (titin) truncation mutations (~25% of familial DCM), LMNA (lamin A/C) mutations (with conduction disease), MYH7 and TNNT2 sarcomeric mutations; recommended genetic testing if DCM diagnosed before age 50 or family history of unexplained cardiomyopathy or sudden death
- Risk Factors
- MODIFIABLE: coronary artery disease (65% of cases), hypertension, diabetes, obesity, alcohol excess (>14 drinks/week), cardiotoxic drugs (doxorubicin, trastuzumab) | NON-MODIFIABLE: age >65, male sex, African-American ethnicity (1.5× higher risk), familial cardiomyopathy
- Biomarkers
- NT-proBNP (>300 pg/mL for diagnosis; serial monitoring for treatment response; >1000 pg/mL associated with poor prognosis), BNP >100 pg/mL, high-sensitivity troponin (chronic elevation indicates ongoing myocardial injury), sST2 and galectin-3 (fibrosis markers)
The neurohormonal cascade that defines HFrEF pathophysiology begins within hours of the initial myocardial insult. Reduced stroke volume activates carotid and aortic baroreceptors, triggering sympathetic nervous system activation that increases heart rate and contractility through beta-1 adrenergic stimulation. Simultaneously, reduced renal perfusion pressure activates the renin-angiotensin-aldosterone system (RAAS), generating angiotensin II, which causes arteriolar vasoconstriction (increasing afterload) and stimulates aldosterone secretion (promoting sodium and water retention). While these compensatory mechanisms temporarily maintain cardiac output, chronic neurohormonal activation becomes profoundly maladaptive. Sustained norepinephrine exposure causes beta-1 receptor downregulation and direct cardiomyocyte apoptosis. Angiotensin II and aldosterone stimulate cardiac fibroblast proliferation, increasing interstitial collagen deposition and myocardial stiffness. The natriuretic peptide system (ANP, BNP) attempts counterregulation through vasodilation and natriuresis, but becomes overwhelmed as disease progresses. Endothelin-1 and arginine vasopressin contribute additional vasoconstriction and free water retention. This neurohormonal imbalance drives the hallmark structural changes of HFrEF: eccentric hypertrophy (sarcomeres added in series), ventricular dilation, mitral annular dilation producing functional mitral regurgitation, and progressive reduction in ejection fraction. The transition from compensated to decompensated heart failure occurs when these mechanisms fail to maintain adequate end-organ perfusion, manifesting as exertional dyspnea, fluid retention, and ultimately cardiogenic shock.
Diagnostic Protocol
The diagnosis of HFrEF requires the combination of signs and symptoms of heart failure with objective evidence of reduced left ventricular systolic function on imaging. Suspect heart failure in any patient presenting with dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, or unexplained fatigue. Initial evaluation includes a comprehensive history focusing on cardiac risk factors, family history of cardiomyopathy, alcohol and drug exposure, and prior cardiotoxic chemotherapy. Physical examination findings of elevated jugular venous pressure, S3 gallop, displaced apical impulse, hepatojugular reflux, and bilateral crackles support the diagnosis. Grade A The two-axis classification system uses NYHA functional class (I–IV) to describe symptomatic limitation and ACC/AHA stages (A–D) to define disease progression, recognizing that staging is unidirectional while functional class may improve with therapy.
NYHA Functional Classification
| Class | Symptom Description | Exercise Tolerance | Prognosis / 1-Year Mortality |
|---|---|---|---|
| Class I | No limitation of physical activity; ordinary activity does not cause dyspnea, fatigue, or palpitations | Can perform ≥7 METs | 5–10% annual mortality |
| Class II | Slight limitation; comfortable at rest but ordinary activity causes dyspnea or fatigue | 5–7 METs | 10–15% annual mortality |
| Class III | Marked limitation; comfortable at rest but less-than-ordinary activity causes symptoms | 2–5 METs | 15–25% annual mortality |
| Class IV | Unable to carry out any physical activity without discomfort; symptoms at rest | <2 METs | 30–50% annual mortality |
ACC/AHA Heart Failure Staging
| Stage | Definition | Example | Management Focus |
|---|---|---|---|
| Stage A | At risk for HF but no structural disease or symptoms | HTN, DM, CAD, cardiotoxin exposure, family history of CM | Risk factor modification; ACEi/ARB if indicated for comorbidity |
| Stage B | Structural heart disease but no symptoms of HF | Previous MI, LV remodeling, asymptomatic valvular disease, LVEF <50% | ACEi/ARB + beta-blocker; ICD if LVEF ≤30% and ischemic |
| Stage C | Structural heart disease with prior or current HF symptoms | Known HFrEF with dyspnea, fatigue, reduced exercise tolerance | Full four-pillar GDMT + device therapy + cardiac rehab |
| Stage D | Refractory HF requiring advanced interventions | Persistent NYHA IV despite optimized GDMT; recurrent hospitalizations; inotrope dependence | Transplant evaluation, LVAD, palliative care, hospice |
Diagnostic Workup
| Test | Rationale / What It Shows | Sensitivity | Specificity |
|---|---|---|---|
| Transthoracic Echocardiography (TTE) | Definitive assessment of LVEF, chamber dimensions, wall motion, valvular function, diastolic parameters, RV function, estimated RVSP | 90–95% (for LVEF <40%) | 95–98% |
| NT-proBNP / BNP | Natriuretic peptide levels for diagnosis (NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL), prognosis, and treatment monitoring | 90–95% | 65–75% |
| 12-Lead ECG | Identifies arrhythmias, conduction delays (LBBB for CRT candidacy), ischemic changes, LVH, low voltage (infiltrative) | 75–85% (for any abnormality in HF) | 25–40% |
| Cardiac MRI (CMR) | Gold standard for LVEF measurement, myocardial characterization (LGE for scar/fibrosis, T1/T2 mapping for edema/infiltration), identifies etiology | 95–98% | 95–98% |
| Coronary Angiography / CTA | Evaluate for CAD as etiology; revascularizable ischemia may improve LVEF; required in new-onset HFrEF | 95–99% (for obstructive CAD) | 85–95% |
Differential Diagnosis
| Condition | Distinguishing Feature | Key Workup |
|---|---|---|
| HFpEF (LVEF ≥50%) | Preserved LVEF with diastolic dysfunction; concentric remodeling; normal chamber size; elevated E/e’ ratio >14 | TTE with tissue Doppler; exercise hemodynamics if diagnosis uncertain |
| Pulmonary Disease (COPD, PE) | Dyspnea with preserved LVEF; hyperinflated lungs, wheezing; hypoxemia without crackles; normal BNP in isolated lung disease | Chest CT, PFTs, CTPA; BNP <100 pg/mL argues against HF |
| Valvular Heart Disease | Primary valvular lesion (severe AS, severe MR) causing secondary LV dysfunction; murmur precedes HF symptoms | TTE with Doppler assessment; TEE if needed; cardiac catheterization pre-surgery |
| Cardiac Amyloidosis | LVH with low voltage on ECG; restrictive physiology; biatrial dilation; apical sparing on strain imaging | Technetium pyrophosphate scan (ATTR), serum/urine free light chains (AL), cardiac MRI, endomyocardial biopsy |
| Thyrotoxicosis / High-Output HF | Tachycardia, warm peripheries, wide pulse pressure, high cardiac output; may present as atrial fibrillation with rapid ventricular response | TSH, free T4; TTE shows hyperdynamic LV; treat underlying cause |
Treatment Algorithm
Modern HFrEF management centers on the four pillars of guideline-directed medical therapy (GDMT), each targeting a distinct neurohormonal pathway. The paradigm has shifted from slow sequential titration to rapid simultaneous initiation of all four drug classes at low starting doses, followed by uptitration at 2–4 week intervals to target doses. Grade A This approach reduces the time patients spend on suboptimal therapy and achieves an estimated 73% relative reduction in cardiovascular death when all four pillars reach target doses compared to no therapy. Device therapy (ICD, CRT) complements GDMT in selected patients after a 3-month optimization period.
Start all four drug classes at low doses within 1–2 weeks of diagnosis. Do not wait for full titration of one drug before starting another. Ensure systolic BP ≥100 mmHg and eGFR ≥20 mL/min (for SGLT2i). Each pillar has independent, additive mortality benefit. Grade A
Pillar 1 (ARNI): Sacubitril-valsartan (Entresto): Sacubitril-valsartan 24/26 mg PO BID → target 97/103 mg PO BID
Pillar 2 (Beta-blocker): Carvedilol (Coreg): Carvedilol 3.125 mg PO BID → target 25 mg PO BID (50 mg if >85 kg)
Pillar 3 (MRA): Spironolactone (Aldactone): Spironolactone 12.5-25 mg PO daily → target 25-50 mg PO daily
Pillar 4 (SGLT2i): Dapagliflozin (Farxiga): Dapagliflozin 10 mg PO daily (no titration needed)
Alternative beta-blocker: Metoprolol succinate 12.5-25 mg PO daily → target 200 mg PO daily
Alternative SGLT2i: Empagliflozin 10 mg PO daily (no titration needed)
After ≥3 months of maximally tolerated GDMT, reassess LVEF and QRS morphology. ICD for primary prevention of sudden cardiac death in patients with LVEF ≤35% and NYHA II–III. CRT for patients with LVEF ≤35%, NYHA II–IV, and LBBB with QRS ≥150 ms. CRT-D (defibrillator + resynchronization) is the preferred device when both criteria are met. Grade A
ICD: ICD implantation if LVEF ≤35% + NYHA II-III + ≥1 year life expectancy
CRT-D: CRT-D if LVEF ≤35% + LBBB + QRS ≥150 ms + NYHA II-IV
Additional pharmacotherapy: Hydralazine + Isosorbide dinitrate: Hydralazine 37.5 mg + ISDN 20 mg PO TID → target 75/40 mg TID (if ARNI/ACEi/ARB not tolerated, or as add-on in self-identified Black patients) Grade B
If heart rate >70 bpm in sinus rhythm on maximized beta-blocker: Ivabradine (Corlanor): Ivabradine 2.5 mg PO BID → target 7.5 mg PO BID
Refer to an advanced HF center when Stage D criteria are met: persistent NYHA IV symptoms despite optimized GDMT and device therapy, ≥2 HF hospitalizations in 12 months, need for continuous or intermittent IV inotropes, or progressive renal/hepatic dysfunction attributable to HF. Cardiac transplant remains the gold standard for eligible patients (<70 years, no fixed pulmonary hypertension, no active malignancy). LVAD serves as bridge-to-transplant or destination therapy. Grade B
Bridge inotrope support: Dobutamine 2-5 mcg/kg/min IV continuous or Milrinone 0.375-0.75 mcg/kg/min IV continuous
Special Populations
| Population | Drug / Consideration | Specific Recommendation |
|---|---|---|
| Renal Impairment | ARNI / MRA / SGLT2i | Sacubitril-valsartan: start 24/26 mg BID if eGFR 15–30 (no data <15). Spironolactone: avoid if K+ >5.0 or eGFR <30; check K+ at 1 and 4 weeks. SGLT2i: initiate if eGFR ≥20; expect transient eGFR dip (3–5 mL/min) that stabilizes |
| Hepatic Impairment | Carvedilol | Carvedilol: contraindicated in decompensated cirrhosis (Child-Pugh C); use bisoprolol 1.25 mg daily as alternative (not extensively hepatic metabolized). All beta-blockers: caution in advanced liver disease with portal HTN |
| Elderly (≥75) | All GDMT pillars | Same target doses as younger patients. Start at lowest dose and uptitrate slowly (q4 weeks). Monitor orthostatic BP at each visit. Frailty assessment guides intensity of therapy; do not withhold GDMT based on age alone |
| Pregnancy | ACEi / ARB / ARNI / MRA | ARNI, ACEi, ARB, MRA are absolutely contraindicated in pregnancy (teratogenic: renal agenesis, oligohydramnios). Switch to hydralazine + nitrate for afterload reduction. Beta-blockers: labetalol or metoprolol succinate are safe. SGLT2i: insufficient data, discontinue |
| Pediatric | ACEi / Beta-blocker | Enalapril 0.1 mg/kg/dose PO BID (max 0.5 mg/kg/day). Carvedilol 0.05 mg/kg PO BID (titrate to 0.35 mg/kg BID). ARNI and SGLT2i: limited pediatric data; use ACEi as first-line. MRA: spironolactone 1–3 mg/kg/day |
| Black Patients | Hydralazine-ISDN add-on | Add hydralazine 37.5 mg + ISDN 20 mg TID to standard GDMT (A-HeFT trial: 43% mortality reduction in self-identified Black patients). Titrate to 75/40 mg TID as tolerated |
Drug Interactions
| Drug | Interacting Agent | Mechanism | Clinical Effect | Management |
|---|---|---|---|---|
| Sacubitril-valsartan | ACE inhibitors | Combined neprilysin and ACE inhibition increases bradykinin and substance P accumulation | Life-threatening angioedema | Mandatory 36-hour washout from last ACEi dose before initiating ARNI; never co-administer |
| Spironolactone | Potassium supplements / TMP-SMX | Additive potassium retention via ENaC blockade (TMP) and aldosterone antagonism (spironolactone) | Severe hyperkalemia (K+ >6.0), cardiac arrhythmia risk | Discontinue K+ supplements when starting MRA; avoid TMP-SMX; check K+ within 3 days if co-prescribed. Use patiromer 8.4 g daily if persistent K+ 5.1–5.5 to enable MRA continuation |
| Carvedilol | Verapamil / Diltiazem | Combined AV nodal suppression (beta-blocker + non-DHP CCB) | Severe bradycardia, AV block, hemodynamic collapse | Avoid combination; if rate control needed, use digoxin (loading 0.25 mg IV × 2, maintenance 0.125–0.25 mg PO daily adjusted to level 0.5–0.9 ng/mL) |
| All RAAS inhibitors | NSAIDs (ibuprofen, naproxen) | NSAIDs inhibit renal prostaglandins → reduce GFR, impair natriuresis, blunt RAAS inhibitor efficacy | Acute kidney injury, fluid retention, worsening HF, hyperkalemia | Avoid all NSAIDs in HFrEF; use acetaminophen 500–1000 mg PO q6h PRN for pain; topical diclofenac for localized musculoskeletal pain |
| Dapagliflozin | Loop diuretics | Additive diuretic/natriuretic effect via osmotic glycosuria (SGLT2i) + loop of Henle blockade | Volume depletion, hypotension, AKI (especially in elderly or CKD) | Reduce loop diuretic dose by 25–50% when initiating SGLT2i if patient is euvolemic; monitor weight, BP, and renal function at 1–2 weeks |
Monitoring & Surveillance
Monitoring in HFrEF has three intertwined goals: optimizing GDMT titration, detecting decompensation early, and surveilling for treatment-related adverse effects. The initial 3–6 months after diagnosis are the most intensive monitoring period, during which all four GDMT pillars are being uptitrated to target doses. Serial assessment of blood pressure, heart rate, renal function, and electrolytes guides the pace and safety of titration. After stabilization, structured follow-up every 3–6 months with natriuretic peptide trends, LVEF reassessment, and volume status evaluation provides the framework for long-term management. Daily weight monitoring by the patient remains the most practical tool for early detection of fluid retention, with instructions to contact the clinic for weight gain exceeding 2 kg over 2–3 days.
- TTE: LVEF, LV dimensions, wall motion, valves, RVSP
- NT-proBNP (or BNP) for baseline prognosis
- BMP: creatinine, eGFR, K+, Na+
- CBC, iron studies (ferritin, TSAT), TSH, LFTs, HbA1c
- 12-lead ECG (rhythm, QRS duration/morphology)
- BMP: K+ and creatinine (critical with MRA + ARNI)
- Blood pressure (orthostatic if symptomatic)
- Heart rate (target <70 bpm in sinus rhythm)
- Volume status: weight, JVP, peripheral edema
- NT-proBNP trend (declining = good response)
- BMP: K+, creatinine, eGFR
- NYHA functional class reassessment
- Iron studies annually (IV iron if ferritin <100 or ferritin 100–299 + TSAT <20%)
- LVEF reassessment at 3–6 months (ICD/CRT decision)
- Annual echo if stable (detect progressive remodeling)
- Sooner if clinical change (new murmur, worsening symptoms)
Response & Safety Parameters
| Parameter | Target / Threshold | Frequency | Action if Abnormal |
|---|---|---|---|
| Serum Potassium | 3.5–5.0 mEq/L | 1–2 weeks after MRA/ARNI change; then q3 months | K+ 5.1–5.5: reduce MRA dose by 50%, recheck in 1 week. K+ >5.5: hold MRA, recheck in 48h; consider patiromer. K+ >6.0: hold MRA + ARNI, ECG, emergent treatment |
| Serum Creatinine / eGFR | eGFR stable (<30% increase in Cr from baseline) | 1–2 weeks after dose changes; then q3 months | Cr increase >30%: check volume status, hold diuretics if dry, reduce ARNI dose. Cr increase >50% or eGFR <15: hold ARNI/MRA, nephrology consult |
| Systolic Blood Pressure | ≥90 mmHg (asymptomatic hypotension tolerable) | Each visit; daily at home if unstable | SBP <90 with symptoms: reduce diuretics first, then reduce ARNI dose. Persistent symptomatic hypotension: consider switching ARNI to lower-dose ARB |
| NT-proBNP | Declining trend (30%+ reduction from baseline = favorable) | Baseline, 3 months, 6 months, then annually | Rising NT-proBNP despite GDMT: reassess volume status, consider non-compliance, evaluate for new arrhythmia (AF), repeat TTE |
| Heart Rate (sinus rhythm) | <70 bpm at rest | Each visit | HR >70 on maximized beta-blocker: add ivabradine 2.5 mg BID (sinus rhythm only; contraindicated in AF) |
Clinical Commentary
Advanced HF / Transplant Center: (4) ≥2 HF hospitalizations in 12 months despite maximized therapy. (5) Inotrope dependence or inability to wean IV diuretics. (6) Peak VO2 <14 mL/kg/min on cardiopulmonary exercise testing — transplant evaluation.
Emergency / ICU: (7) Cardiogenic shock (SBP <90, lactate >2, end-organ dysfunction) — immediate ICU transfer for invasive hemodynamic monitoring and inotrope/mechanical support.
- Optimal management of HFrEF patients whose LVEF recovers to >40% on GDMT (HFimpEF): whether therapy can be safely reduced or must continue indefinitely to prevent relapse
- Role of novel agents (vericiguat, omecamtiv mecarbil) as additional pillars beyond the current four in patients with persistent symptoms
- Optimal patient selection and timing for percutaneous mitral valve repair (MitraClip) in functional mitral regurgitation complicating HFrEF
Practice Insights: HFrEF After the Four-Pillar-Simultaneous Pivot
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Because each month a patient with HFrEF spends on partial therapy carries avoidable mortality risk, the GDMT initiation pattern has compressed dramatically. The textbook still describes sequential titration over 3 to 6 months — ACEi first, beta-blocker after stabilization, MRA when stable, SGLT2i added on. In experienced practice all four pillars now go on the patient at low doses within the same hospital admission or the first two clinic visits, with rapid titration over 4 to 6 weeks. The patients experienced clinicians have followed under this fast-sequence approach have measurably better 6-month reverse remodeling than the slow-ladder cohort experienced clinicians trained with — and the difference shows up on echo, not just on hospitalization curves.
Four pillars in 14 days, target doses in 4-6 weeks
The STRONG-HF trial confirmed what seasoned clinicians had been doing pragmatically: simultaneous initiation of ARNI + beta-blocker + MRA + SGLT2i within the first 2 weeks of HFrEF diagnosis, with rapid uptitration to target doses by week 4-6, cuts 180-day all-cause death or HF readmission by 34 percent compared to usual care. They have stopped staggering pillars over months. Low starting doses, frequent check-ins (week 1, 2, 4, 6 visits or phone), labs at each touch — this is how experienced practitioners now run new HFrEF.
ARNI first, not ACEi — Experienced Clinicians skip the ACEi step entirely
For any new HFrEF diagnosis with systolic BP > 100 mmHg and eGFR > 30, seasoned clinicians initiate sacubitril-valsartan 24/26 mg BID directly without going through an ACEi trial first. PARADIGM-HF showed 20% relative mortality reduction over enalapril; PIONEER-HF showed ARNI initiation during HF hospitalization is safe. The classical “stabilize on ACEi, then switch to ARNI” pathway costs the patient 4-8 weeks of suboptimal therapy. Experienced practitioners reserve ACEi only if cost is a hard barrier — and even then they have transitioned almost everyone to ARNI within 3 months.
Iron deficiency is screened on every HF patient, every hospitalization
experienced clinicians check ferritin + TSAT on every new HFrEF diagnosis and every HF hospitalization. The threshold for treatment in HF (ferritin < 100 OR ferritin 100-299 with TSAT < 20%) is more generous than for general iron-deficiency anemia because of HF-related inflammation. IV ferric carboxymaltose 15 mg/kg up to 1000 mg per dose is the only modality seasoned clinicians use — oral iron does not improve HF outcomes and they no longer prescribe it. Roughly half of the new HFrEF patients qualify, and the functional improvement (6MWD +30-40 m at 6 months) is dramatic in responders.
Patiromer to keep MRA on, not drop it
Hyperkalemia in the K+ 5.5-6.0 range triggers most internists to stop spironolactone. Experienced practitioners do the opposite: add patiromer 8.4 g daily or sodium zirconium cyclosilicate 5 g daily and keep the MRA on at target dose. The mortality benefit of MRA is too large to give up for a manageable K+ excursion. DIAMOND supported this approach. They reserve MRA discontinuation only for refractory K+ > 6.0 despite maximal binder dose, or for clinical hyperkalemia toxicity.
Anonymized Case: New HFrEF EF 25%, NYHA III, Same-Admission Four-Pillar Start
A man in his late fifties was admitted with new-onset HF symptoms, presenting with NYHA class III dyspnea, bilateral lower extremity edema, LVEF 25% on TTE, NT-proBNP 8,500 pg/mL, no diabetes, K+ 4.6, eGFR 65, systolic BP 118 mmHg. The treating clinicians started furosemide 40 mg IV for diuresis, and on hospital day 2 (once euvolemic-trending) they initiated all four GDMT pillars: sacubitril-valsartan 24/26 mg BID, bisoprolol 2.5 mg daily, spironolactone 12.5 mg daily, dapagliflozin 10 mg daily. Iron studies showed ferritin 65, TSAT 17% — ferric carboxymaltose 1000 mg IV before discharge. By week 6 he was at sacubitril-valsartan 49/51 mg BID, bisoprolol 5 mg, spironolactone 25 mg, dapagliflozin unchanged. At 6 months follow-up: LVEF 38%, NYHA II, NT-proBNP 1,500, 6MWD up 75 meters from baseline.
Four Protocol Deviations Experienced Clinicians Now Default To
- Simultaneous four-pillar initiation (ARNI + BB + MRA + SGLT2i) within 14 days of new HFrEF diagnosis, target doses by week 4-6. Per STRONG-HF, this approach cuts 180-day death or HF readmission by 34% versus sequential staggering. Low starting doses + frequent labs/visits make the fast sequence safe.
- ARNI first, skip ACEi entirely for new HFrEF with SBP > 100 + eGFR > 30. Sacubitril-valsartan 24/26 mg BID from day one (in-hospital initiation per PIONEER-HF is safe). Seasoned clinicians reserve ACEi only when cost is a hard barrier.
- IV ferric carboxymaltose for any HFrEF patient with ferritin < 100 OR (ferritin 100-299 + TSAT < 20%). No oral iron. Screen at diagnosis and at every HF hospitalization. Functional improvement (6MWD +30-40 m at 6 months) is one of the most reliable wins in the HF clinic.
- Patiromer or sodium zirconium to enable MRA continuation when K+ rises to 5.5-6.0; do not drop spironolactone for hyperkalemia in this range. Vericiguat 10 mg daily added on top of optimized four-pillar GDMT for patients with worsening event in the prior 6 months (VICTORIA).
Frequently Asked Questions
- Heart Failure with Preserved Ejection Fraction: Diagnosis and Management
- Complete Heart Block: Diagnosis and Management
- Stable Ischemic Heart Disease: Diagnosis and Optimal Medical Therapy
- Takotsubo Cardiomyopathy: Diagnosis and Management
- Tricuspid Regurgitation: Diagnosis and Management
- Atrial Fibrillation — Diagnosis and Comprehensive Management